Hutchmed (China) Limited Vesting of awards under the LTIP
21 Octubre 2024 - 3:30AM
RNS Regulatory News
RNS Number : 9386I
Hutchmed (China) Limited
21 October 2024
Vesting of awards under the Long
Term Incentive Plan
Hong
Kong, Shanghai & Florham Park, NJ - Monday, October 21,
2024: HUTCHMED (China) Limited
("HUTCHMED")
(Nasdaq/AIM: HCM; SEHK:13) announces that the non-performance based
awards granted under the Long Term Incentive Plan ("LTIP") on
October 20, 2021 to the following persons discharging managerial
responsibilities were vested on October 20, 2024:-
|
|
|
Number of American depositary
shares ("ADS")
|
|
|
|
|
|
Dr Dan
Eldar (Non-executive Director ("NED"))
|
|
1,938
|
|
Ms Edith
Shih (NED)
|
|
1,938 (1)
|
|
Mr Paul
Carter (Independent Non-executive Director ("INED"))
|
|
1,647 (2)
|
|
Mr Graeme
Jack (INED)
|
|
1,938
|
|
Professor
Tony Mok (INED)
|
|
1,938
|
Notes:
(1) These ADSs were not
received by Ms Edith Shih, but were received by or for the account
of her employer, Hutchison International Limited.
(2) Mr Paul Carter
elected, on acceptance of the grant of his awards, to have 15% of
his LTIP awards (amounting to US$9,375 with respect to his awards
which vested on October 20, 2024) held on his behalf by the
trustee administering the LTIP pending vesting in the form of cash,
to settle his tax liabilities in respect of his awards.
(3) Since the vesting date is not a trading day, the relevant ADSs
are scheduled to be transferred to the award holders on October 21,
2024.
The notifications set out
below are provided
in accordance with the requirements of the UK Market Abuse
Regulation.
(a)
Dr Dan Eldar
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Dr Dan Eldar
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Non-Executive Director
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
HUTCHMED (China) Limited
|
|
b)
|
LEI
|
2138006X34YDQ6OBYE79
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
Identification code
|
ADS each
representing five Ordinary Shares of US$0.10
ADS ISIN:
US44842L1035
|
|
b)
|
Nature of the transaction
|
Vesting of awards granted on
October 20, 2021 under HUTCHMED's LTIP
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
Nil
|
1,938 ADS
|
|
|
d)
|
Aggregated information
|
-
|
Aggregated volume
|
|
-
|
Price
|
|
N/A
|
|
e)
|
Date of the transaction
|
2024-10-20
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
(b)
Mr Paul Carter
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Mr Paul Carter
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Independent Non-Executive
Director
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
HUTCHMED (China) Limited
|
|
b)
|
LEI
|
2138006X34YDQ6OBYE79
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
Identification code
|
ADS each
representing five Ordinary Shares of US$0.10
ADS ISIN:
US44842L1035
|
|
b)
|
Nature of the transaction
|
Vesting of awards granted on
October 20, 2021 under
HUTCHMED's LTIP
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
Nil
|
1,647 ADS
|
|
|
d)
|
Aggregated information
|
-
|
Aggregated volume
|
|
-
|
Price
|
|
N/A
|
|
e)
|
Date of the transaction
|
2024-10-20
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
(c)
Mr Graeme Jack
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Mr Graeme Jack
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Independent Non-Executive
Director
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
HUTCHMED (China) Limited
|
|
b)
|
LEI
|
2138006X34YDQ6OBYE79
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
Identification code
|
ADS each
representing five Ordinary Shares of US$0.10
ADS ISIN:
US44842L1035
|
|
b)
|
Nature of the transaction
|
Vesting of awards granted on
October 20, 2021 under
HUTCHMED's LTIP
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
Nil
|
1,938 ADS
|
|
|
d)
|
Aggregated information
|
-
|
Aggregated volume
|
|
-
|
Price
|
|
N/A
|
|
e)
|
Date of the transaction
|
2024-10-20
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
(d)
Professor Tony Mok
|
1
|
Details of the person discharging managerial
responsibilities/person closely associated
|
|
a)
|
Name
|
Professor Tony Mok
|
|
2
|
Reason for the notification
|
|
a)
|
Position/status
|
Independent Non-Executive
Director
|
|
b)
|
Initial
notification/Amendment
|
Initial notification
|
|
3
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
|
a)
|
Name
|
HUTCHMED (China) Limited
|
|
b)
|
LEI
|
2138006X34YDQ6OBYE79
|
|
4
|
Details of the transaction(s): section to be repeated for (i)
each type of instrument; (ii) each type of transaction; (iii) each
date; and (iv) each place where transactions have been
conducted
|
|
a)
|
Description
of the financial instrument, type of instrument
Identification code
|
ADS each
representing five Ordinary Shares of US$0.10
ADS ISIN:
US44842L1035
|
|
b)
|
Nature of the transaction
|
Vesting of awards granted on
October 20, 2021 under
HUTCHMED's LTIP
|
|
c)
|
Price(s) and volume(s)
|
|
Price(s)
|
Volume(s)
|
|
Nil
|
1,938 ADS
|
|
|
d)
|
Aggregated information
|
-
|
Aggregated volume
|
|
-
|
Price
|
|
N/A
|
|
e)
|
Date of the transaction
|
2024-10-20
|
|
f)
|
Place of the transaction
|
Outside a trading venue
|
About HUTCHMED
HUTCHMED (Nasdaq/AIM:HCM; HKEX:13) is an innovative,
commercial-stage, biopharmaceutical company. It is committed to the
discovery, global development and commercialization of targeted
therapies and immunotherapies for the treatment of cancer and
immunological diseases. It has approximately 5,000 personnel across
all its companies, at the center of which is a team of about 1,800
in oncology/immunology. Since inception, HUTCHMED has focused on
bringing cancer drug candidates from in-house discovery to patients
around the world, with its first three medicines marketed in China,
the first of which is also marketed in the US and Europe. For more
information, please visit: www.hutch-med.com or follow us on
LinkedIn.
CONTACTS
Investor Enquiries
|
+852 2121 8200 /
ir@hutch-med.com
|
|
|
|
Media Enquiries
|
|
|
Ben Atwell / Alex Shaw,
FTI Consulting
|
+44 20 3727 1030 /
+44 7771 913 902 (Mobile) /
+44 7779 545 055 (Mobile) / HUTCHMED@fticonsulting.com
|
|
Zhou Yi, Brunswick
|
+852 9783 6894 (Mobile) /
HUTCHMED@brunswickgroup.com
|
|
|
|
Nominated Advisor
|
|
|
Atholl Tweedie / Freddy Crossley /
Rupert Dearden, Panmure Liberum
|
+44 (20) 7886 2500
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our
Privacy
Policy.
END
DSHMBBRTMTBTMTI
Hutchmed (china) (LSE:HCM)
Gráfica de Acción Histórica
De Oct 2024 a Nov 2024
Hutchmed (china) (LSE:HCM)
Gráfica de Acción Histórica
De Nov 2023 a Nov 2024
